EventsThe 3rd International Electronic Conference on Cancers: New Targets for Cancer Therapies (IECC 2023)
Published
This submission belongs to the session S1. Genome-wide Approaches for Target Identification. of the event The 3rd International Electronic Conference on Cancers: New Targets for Cancer Therapies (IECC 2023)
Published date
24 Mar, 2023
Academic Editor
author-avatarCarlos Moreno
Citation
Deepesh Kumar Verma, Dr. Akhileshwar Namani, "RUNX1-regulated pathways and biomarkers in Acute Myeloid Leukemia", in Proceedings of The 3rd International Electronic Conference on Cancers: New Targets for Cancer Therapies (IECC 2023), 16 March–30 March 2023, MDPI: Basel, Switzerland, doi: 10.3390/IECC2023-14279
Share
Email
Facebook
Twitter
LinkedIn

"RUNX1-regulated pathways and biomarkers in Acute Myeloid Leukemia"

Dr. Akhileshwar Namani 2
1. Department of Biotechnology, GITAM UNIVERSITY, VISAKHAPATNAM, INDIA, India
2. Department of Biotechnology, GITAM UNIVERSITY, VISAKHAPATNAM, INDIA
Abstract

Runt-related transcription factor 1 gene (RUNX1), also known as acute myeloid leukemia 1 protein (AML1), plays a critical role in the pathogenesis of AML. One of leukemia's most frequently mutated genes is RUNX1/AML1, which is related to a poor prognosis in AML. Researchers and clinicians can design personalized medicines and enhance diagnosis by identifying biomarkers linked to genetic mutations. In the current study, we used TCGA-Acute Myeloid Leukemia (AML) cohort's genomic and transcriptome data. We analyzed RUNX1 mutated AML patients to non-mutated patients using an integrated, multi-omics, multi-database analysis of exome and transcriptomics data. The mutation landscape of several genes, including RUNX1 mutations, was revealed by TCGA-AML data from multi-center high-throughput exome sequencing. Finally, we identified the gene signature associated with RUNX1 mutations, including prognostic genes that significantly impacted the overexpression of the RUNX1 pathway in RUNX1 mutated AML patients. Our findings may help diagnose AML patients with RUNX1 mutations early.

Keywords
RUNX1
AML
leukemia
biomarkers
multi-omics
Manuscript
Oral Presentation
Poster
Deepesh Kumar Verma, RUNX1 PPT for SciForm.pdf
PLGA nanoparticles loaded with cinnamon exctract and coated with PVA/poloxamer188